Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Massachusetts startup SynapDx announced on Wednesday that it will work with DNA sequencer manufacturer Illumina  to develop early detection tools for autism spectrum disorders,  according to a release.

SynapDx is trying to develop a blood-based test that will catch most cases of autism spectrum disorders in children earlier than current methods (see “Can a Blood Test Detect Autism Early?”). The advantage would be that treatments seem to work better the sooner they start. The challenge is that there aren’t clear biomarkers or genetic signals for the disorder, which is most likely a mix of many different conditions.

But that doesn’t seem to deter sequencing giant Illumina, which has been growing the diagnostic side of its business over the last few months (see “A Brave New World of Prenatal DNA Sequencing”). According to the release:

“SynapDx and Illumina share a vision of better pediatric care through the use of advanced molecular assays and sequencing technologies,” said Stanley Lapidus, SynapDx’s CEO. “We look forward to broadly collaborating on multiple joint initiatives.”

SynapDx is currently recruiting participants into a clinical study of gene expression and autism in children less than 5 years old, which might help them identify biomarkers of the condition.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me